Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02727660
Recruitment Status : Completed
First Posted : April 4, 2016
Results First Posted : September 26, 2019
Last Update Posted : September 26, 2019
Sponsor:
Information provided by (Responsible Party):
Pearl Therapeutics, Inc.

Brief Summary:
This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study with PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disorder Drug: BFF MDI (PT009) 320/9.6 μg Drug: BFF MDI (PT009) 160/9.6 μg Drug: FF MDI (PT005) 9.6 μg Phase 3

Detailed Description:
This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study. Subjects will undergo a 1- to 4-week Screening Period. Subjects who successfully complete the Screening Period will be randomized to one of the following three treatment groups: PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID. Following randomization, subjects will enter the Treatment Period and undergo additional treatment visits over 52 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1876 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Actual Study Start Date : April 29, 2016
Actual Primary Completion Date : April 4, 2018
Actual Study Completion Date : April 4, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BFF MDI (PT009) 320/9.6 μg
Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
Drug: BFF MDI (PT009) 320/9.6 μg
Blinded Treatment
Other Name: Budesonide and Formoterol Fumarate Inhalation Aerosol

Experimental: BFF MDI (PT009) 160/9.6 μg
Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
Drug: BFF MDI (PT009) 160/9.6 μg
Blinded Treatment
Other Name: Budesonide and Formoterol Fumarate Inhalation Aerosol

Experimental: FF MDI (PT005) 9.6 μg
Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
Drug: FF MDI (PT005) 9.6 μg
Blinded Treatment
Other Name: Formoterol Fumarate Inhalation




Primary Outcome Measures :
  1. Morning Pre-dose Trough FEV1 [ Time Frame: at Week 12 ]
    Morning pre-dose trough FEV1 (Forced Expiratory Volume in one second) at week 12


Secondary Outcome Measures :
  1. Time to First Moderate or Severe COPD Exacerbation [ Time Frame: over 52 weeks ]
    Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation over 52 weeks

  2. Change From Baseline in Average Daily Rescue Ventolin HFA Use [ Time Frame: over 12 weeks ]
    Change from baseline in average daily rescue Ventolin HFA use over 12 weeks

  3. Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in Saint George's Respiratory Questionnaire (SGRQ) Total Score [ Time Frame: at Week 12 ]
    The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI on health-related quality of life as compared to FF MDI in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. A decrease from baseline in SGRQ total score of 4 units or more is considered a clinically meaningful improvement in quality of life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Give their signed written informed consent to participate
  2. At least 40 years of age and no older than 80 years of age
  3. COPD patients who are symptomatic
  4. Must be receiving one or more inhaled bronchodilators as maintenance therapy
  5. Must have a documented history of COPD exacerbations

Exclusion Criteria:

  1. Current diagnosis of asthma
  2. COPD due to α1-Antitrypsin Deficiency
  3. Known active tuberculosis, lung cancer, cystic fibrosis, and significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months.
  4. Long-term-oxygen therapy (≥ 15 hours a day).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02727660


  Hide Study Locations
Locations
Layout table for location information
United States, Alabama
Research Site
Dothan, Alabama, United States, 36305
Research Site
Huntsville, Alabama, United States, 35801
Research Site
Sheffield, Alabama, United States, 35660
United States, Arizona
Research Site
Flagstaff, Arizona, United States, 86001
United States, California
Research Site
Costa Mesa, California, United States, 92627
Research Site
Gold River, California, United States, 95670
Research Site
Lincoln, California, United States, 95648
Research Site
Long Beach, California, United States, 90822
Research Site
Palo Alto, California, United States, 94304
Research Site
San Diego, California, United States, 92103
Research Site
San Diego, California, United States, 92117
Research Site
San Diego, California, United States, 92120
Research Site
Upland, California, United States, 91786
Research Site
Yorba Linda, California, United States, 92886
United States, Colorado
Research Site
Boulder, Colorado, United States, 80301
Research Site
Denver, Colorado, United States, 80246
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06716
United States, Florida
Research Site
Boynton Beach, Florida, United States, 33472
Research Site
Chiefland, Florida, United States, 32626
Research Site
Clearwater, Florida, United States, 33765
Research Site
Daytona Beach, Florida, United States, 32117
Research Site
Hialeah, Florida, United States, 33012
Research Site
Kissimmee, Florida, United States, 34741
Research Site
Leesburg, Florida, United States, 34748
Research Site
Lehigh Acres, Florida, United States, 33971
Research Site
Merritt Island, Florida, United States, 32952
Research Site
Miami, Florida, United States, 33126
Research Site
Miami, Florida, United States, 33145
Research Site
Miami, Florida, United States, 33155
Research Site
Miami, Florida, United States, 33165
Research Site
Miami, Florida, United States, 33173
Research Site
Orlando, Florida, United States, 32825
Research Site
Ormond Beach, Florida, United States, 32174
Research Site
Port Orange, Florida, United States, 32127
Research Site
Sarasota, Florida, United States, 34239
Research Site
Tampa, Florida, United States, 33603
Research Site
Tampa, Florida, United States, 33607
Research Site
Winter Park, Florida, United States, 32789
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30345
Research Site
Dacula, Georgia, United States, 30019
Research Site
Decatur, Georgia, United States, 30033
Research Site
Snellville, Georgia, United States, 30078
Research Site
Stockbridge, Georgia, United States, 30281
United States, Illinois
Research Site
Aurora, Illinois, United States, 60506
Research Site
Chicago, Illinois, United States, 60607
Research Site
Peoria, Illinois, United States, 61602
United States, Indiana
Research Site
Brownsburg, Indiana, United States, 46112
Research Site
Evansville, Indiana, United States, 47714
Research Site
Valparaiso, Indiana, United States, 46383
United States, Iowa
Research Site
Iowa City, Iowa, United States, 52242
United States, Kansas
Research Site
Olathe, Kansas, United States, 66061
Research Site
Topeka, Kansas, United States, 66604
United States, Kentucky
Research Site
Hazard, Kentucky, United States, 41701
United States, Louisiana
Research Site
Metairie, Louisiana, United States, 70006
Research Site
Sunset, Louisiana, United States, 70584
United States, Maine
Research Site
Biddeford, Maine, United States, 04005
United States, Minnesota
Research Site
Rochester, Minnesota, United States, 55905
United States, Missouri
Research Site
Chesterfield, Missouri, United States, 63017
Research Site
Kansas City, Missouri, United States, 64128
Research Site
Saint Charles, Missouri, United States, 63301
Research Site
Saint Louis, Missouri, United States, 63122
United States, Nebraska
Research Site
Lincoln, Nebraska, United States, 68510
United States, Nevada
Research Site
Reno, Nevada, United States, 89506
United States, New Jersey
Research Site
Toms River, New Jersey, United States, 08755
United States, New York
Research Site
Bronx, New York, United States, 10459
Research Site
Brooklyn, New York, United States, 11215
Research Site
New York, New York, United States, 10029
Research Site
Syracuse, New York, United States, 13210
United States, North Carolina
Research Site
Gastonia, North Carolina, United States, 28054
Research Site
Hickory, North Carolina, United States, 28601
Research Site
Hickory, North Carolina, United States, 28602
Research Site
Lenoir, North Carolina, United States, 28645
Research Site
Tabor City, North Carolina, United States, 28463
Research Site
Winston-Salem, North Carolina, United States, 27104
United States, Ohio
Research Site
Canton, Ohio, United States, 44718
Research Site
Cincinnati, Ohio, United States, 45242
Research Site
Columbus, Ohio, United States, 43207
Research Site
Columbus, Ohio, United States, 43213
Research Site
Dayton, Ohio, United States, 45417
Research Site
Marion, Ohio, United States, 43302
Research Site
Wooster, Ohio, United States, 44691
United States, Oklahoma
Research Site
Edmond, Oklahoma, United States, 73034
United States, Oregon
Research Site
Medford, Oregon, United States, 97504
Research Site
Portland, Oregon, United States, 97220
United States, Pennsylvania
Research Site
Johnstown, Pennsylvania, United States, 15905
Research Site
Scottdale, Pennsylvania, United States, 15683
Research Site
Wyomissing, Pennsylvania, United States, 19610
United States, Rhode Island
Research Site
Cumberland, Rhode Island, United States, 02864
Research Site
East Providence, Rhode Island, United States, 02914
Research Site
Warwick, Rhode Island, United States, 02886
United States, South Carolina
Research Site
Anderson, South Carolina, United States, 29621
Research Site
Gaffney, South Carolina, United States, 29340
Research Site
Gaffney, South Carolina, United States, 29341
Research Site
Lancaster, South Carolina, United States, 29720
Research Site
Orangeburg, South Carolina, United States, 29118
Research Site
Rock Hill, South Carolina, United States, 29732
Research Site
Seneca, South Carolina, United States, 29678
Research Site
Spartanburg, South Carolina, United States, 29303
United States, Tennessee
Research Site
Franklin, Tennessee, United States, 37067
Research Site
Knoxville, Tennessee, United States, 37909
Research Site
Smyrna, Tennessee, United States, 37167
United States, Texas
Research Site
Amarillo, Texas, United States, 79106
Research Site
Austin, Texas, United States, 78758
Research Site
Baytown, Texas, United States, 77521
Research Site
Dallas, Texas, United States, 75234
Research Site
Houston, Texas, United States, 77030
Research Site
Kerrville, Texas, United States, 78028
Research Site
Lewisville, Texas, United States, 75067
Research Site
Lufkin, Texas, United States, 75904
Research Site
McKinney, Texas, United States, 75069
Research Site
McKinney, Texas, United States, 75070
Research Site
Plano, Texas, United States, 75093
Research Site
Port Arthur, Texas, United States, 77640
Research Site
Sherman, Texas, United States, 75092
Research Site
Spring, Texas, United States, 77379
Research Site
Waco, Texas, United States, 76712
United States, Utah
Research Site
Salt Lake City, Utah, United States, 94102
United States, Virginia
Research Site
Manassas, Virginia, United States, 20110
United States, Washington
Research Site
Everett, Washington, United States, 98208
Research Site
Renton, Washington, United States, 98055
United States, Wisconsin
Research Site
Milwaukee, Wisconsin, United States, 53226
Argentina
Research Site
Buenos Aires, Argentina, C1414AIF
Research Site
Caba, Argentina, 1426
Research Site
Caba, Argentina, C1056ABJ
Research Site
Caba, Argentina, C1425BEN
Research Site
Caba, Argentina
Research Site
Ciudad Autonomade Buenos Aires, Argentina, 1426
Research Site
Ciudad Autónoma de Buenos Aire, Argentina, C1440BRR
Research Site
Ciudad de Buenos Aires, Argentina, 1425
Research Site
Concepción del Uruguay, Argentina, 3260
Research Site
Córdoba, Argentina, X5003DCE
Research Site
Florencio Varela, Argentina, 1888
Research Site
Mar del Plata, Argentina, 7600
Research Site
Mar del Plata, Argentina, B7600FZN
Research Site
Mar del Plata, Argentina, B7600GNY
Research Site
Mendoza, Argentina, 5500
Research Site
Mendoza, Argentina, M5500GIP
Research Site
Nueve de julio, Argentina, B6500EZL
Research Site
Ranelagh, Argentina, 1886
Research Site
Rosario, Argentina, S2000DEJ
Research Site
San Fernando, Argentina, 1646
Research Site
San Miguel de Tucuman, Argentina, 4000
Austria
Research Site
Bludenz, Austria, 6700
Research Site
Feldbach, Austria, A-8330
Research Site
Hallein, Austria, 5400
Research Site
Linz, Austria, 04020
Belgium
Research Site
Brussels, Belgium, 1070
Research Site
Erpent, Belgium, 5101
Research Site
Gilly, Belgium, 6060
Research Site
Jambes, Belgium, 5100
Research Site
Liège, Belgium, 4000
Research Site
Roeselare, Belgium, 8800
Brazil
Research Site
Botucatu, Brazil, 18618-970
Research Site
Porto Alegre, Brazil, 90035074
Research Site
Porto Alegre, Brazil, 90470-340
Research Site
Porto Alegre, Brazil, 90610-000
Research Site
Porto Alegre, Brazil, 91350-200
Research Site
Santo Andre, Brazil, 09080-110
Research Site
Sao Bernardo do Campo, Brazil, 09750-420
Research Site
Sao Paulo, Brazil, 04039-901
Research Site
Sorocaba, Brazil, 18040-425
Research Site
São Paulo, Brazil, 01228-200
Research Site
Uberlandia, Brazil, 38411-186
Research Site
Vitória, Brazil, 29055-450
Canada, Ontario
Research Site
Ajax, Ontario, Canada, L1S 2J5
Research Site
Windsor, Ontario, Canada, N8X 1T3
Research Site
Windsor, Ontario, Canada, N8X 5A6
Canada, Quebec
Research Site
St Charles Borromee, Quebec, Canada, J6E 2B4
Research Site
Trois-Rivières, Quebec, Canada, G8T 7A1
Canada
Research Site
Quebec, Canada, G1V 4G5
Research Site
Quebec, Canada, G2J 0C4
Chile
Research Site
Curico, Chile, 3341643
Research Site
Santiago, Chile, 8380453
Research Site
Santiago, Chile, 8380456
Research Site
Talcahuano, Chile, 4270918
Research Site
Talca, Chile, 3465584
Denmark
Research Site
Aarhus N, Denmark, 8200
Research Site
Hvidovre, Denmark, 2650
Research Site
Kolding, Denmark, 6000
Research Site
København NV, Denmark, 2400
Research Site
Odense C, Denmark, 5000
Research Site
Roskilde, Denmark, 4000
Research Site
Silkeborg, Denmark, 8600
Research Site
Ålborg, Denmark, 9000
Germany
Research Site
Berlin, Germany, 10119
Research Site
Berlin, Germany, 12157
Research Site
Berlin, Germany, 13187
Research Site
Berlin, Germany, 14059
Research Site
Cottbus, Germany, 03044
Research Site
Frankfurt, Germany, 60596
Research Site
Köln, Germany, 51069
Research Site
Leipzig, Germany, 04357
Research Site
Lübeck, Germany, 23552
Research Site
Rodgau-Dudenhofen, Germany, 63110
Italy
Research Site
Bari, Italy, 70124
Research Site
Catania, Italy, 95123
Research Site
Ferrara, Italy, 44121
Research Site
Legnago, Italy, 37045
Research Site
Monza, Italy, 20900
Research Site
Napoli, Italy, 80131
Research Site
Padova, Italy, 35128
Research Site
Pavia, Italy, 27100
Research Site
Riccione, Italy, 47838
Research Site
Rimini, Italy, 47921
Research Site
Roma, Italy, 00100
Research Site
Roma, Italy, 00168
Research Site
Sassari, Italy, 07100
Mexico
Research Site
Cdmx, Mexico, 6760
Research Site
Durango, Mexico, 43080
Research Site
Guadalajara, Mexico, 44100
Research Site
Guadalajara, Mexico, 44130
Research Site
Guadalajara, Mexico, 44200
Research Site
Minatitlán, Mexico, 96730
Research Site
Monterrey, Mexico, 64460
Research Site
Sonora, Mexico, 83000
Research Site
Villahermosa, Mexico, 86035
Norway
Research Site
Arendal, Norway, 4841
Research Site
Hønefoss, Norway, N-3515
Research Site
Kråkeroy, Norway, N-1671
Research Site
Stavanger, Norway, N-4005
Research Site
Svelvik, Norway, 3060
Research Site
Trondheim, Norway, 7030
Peru
Research Site
Chancay, Peru, 15131
Research Site
Cusco, Peru
Research Site
Lima, Peru, 41
Research Site
Lima, Peru, L18
Research Site
Lima, Peru, L27
Research Site
Lima, Peru, L41
Research Site
Lima, Peru, LIMA 1
Research Site
Lima, Peru, LIMA 21
Research Site
Lima, Peru, LIMA 31
Research Site
Lima, Peru, LIMA 32
Research Site
Piura, Peru
Puerto Rico
Research Site
Ponce, Puerto Rico, 00717
Research Site
San Juan, Puerto Rico, 00927
Russian Federation
Research Site
Ekaterinburg, Russian Federation, 620039
Research Site
Izhevsk, Russian Federation, 426035
Research Site
Moscow, Russian Federation, 105077
Research Site
Novosibirsk, Russian Federation, 630008
Research Site
Novosibirsk, Russian Federation, 630084
Research Site
Omsk, Russian Federation, 644043
Research Site
Penza, Russian Federation, 440067
Research Site
Perm, Russian Federation, 614000
Research Site
Saint Petersburg, Russian Federation, 196601
Research Site
Saint-Petersburg, Russian Federation, 197022
Research Site
StPetersburg, Russian Federation, 191180
Research Site
Ulyanovsk, Russian Federation, 432009
South Africa
Research Site
Bloemfontein, South Africa, 9301
Research Site
Cape Town, South Africa, 1730
Research Site
Cape Town, South Africa, 7570
Research Site
Cape Town, South Africa, 7764
Research Site
Durban, South Africa, 4001
Research Site
Johannesburg, South Africa, 2001
Research Site
Lenasia Ext8, South Africa, 1820
Research Site
Mowbray, South Africa, 7700
Research Site
Parow, South Africa
Research Site
Pretoria, South Africa, 184
Research Site
Stanger, South Africa, 4450
Spain
Research Site
Alicante, Spain, 03114
Research Site
Alzira (Valencia), Spain, 46600
Research Site
Benalmádena (Málaga), Spain, 29631
Research Site
Cáceres, Spain, 10003
Research Site
Jerez de la Frontera, Spain, 11407
Research Site
Laredo, Spain, 39770
Research Site
Loja (Granada), Spain, 18300
Research Site
Malaga, Spain, 29010
Research Site
Marbella (Málaga), Spain, 29603
Research Site
Palma de Mallorca, Spain, 07010
Research Site
Sagunto(Valencia), Spain, 46520
Research Site
Sant Boi de Llobregat, Spain, 08830
Sweden
Research Site
Lund, Sweden, 221 85
Research Site
Lund, Sweden, 222 21
Research Site
Malmo, Sweden, 21152
Research Site
Stockholm, Sweden, 114 46
Research Site
Uppsala, Sweden, 75237
United Kingdom
Research Site
Bradford, United Kingdom, BD9 6RJ
Research Site
Chertsey, United Kingdom, KT16 0PZ
Research Site
Chester, United Kingdom, CH2 1UL
Research Site
Doncaster, United Kingdom, DN2 5LT
Research Site
Lancaster, United Kingdom, LA1 4RP
Research Site
Sheffield, United Kingdom, S5 7AU
Research Site
Wishaw, United Kingdom, ML2 0DP
Sponsors and Collaborators
Pearl Therapeutics, Inc.
  Study Documents (Full-Text)

Documents provided by Pearl Therapeutics, Inc.:
Study Protocol  [PDF] January 8, 2018
Statistical Analysis Plan  [PDF] February 9, 2018


Additional Information:
Layout table for additonal information
Responsible Party: Pearl Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02727660     History of Changes
Other Study ID Numbers: PT009003
First Posted: April 4, 2016    Key Record Dates
Results First Posted: September 26, 2019
Last Update Posted: September 26, 2019
Last Verified: August 2019
Keywords provided by Pearl Therapeutics, Inc.:
COPD
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases
Budesonide
Formoterol Fumarate
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action